$7.56
4.18% today
NYSE, Apr 03, 06:45 pm CET
ISIN
US03969F1093
Symbol
RCUS

Arcus Biosciences Stock price

$7.89
-2.61 24.86% 1M
-7.50 48.73% 6M
-7.00 47.01% YTD
-9.83 55.47% 1Y
-27.00 77.39% 3Y
-7.00 47.01% 5Y
-9.11 53.59% 10Y
NYSE, Closing price Wed, Apr 02 2025
+0.18 2.33%
ISIN
US03969F1093
Symbol
RCUS
Sector
Industry

Key metrics

Market capitalization $835.09m
Enterprise Value $16.09m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 0.06
P/S ratio (TTM) P/S ratio 3.24
P/B ratio (TTM) P/B ratio 1.50
Revenue growth (TTM) Revenue growth 120.51%
Revenue (TTM) Revenue $258.00m
EBIT (operating result TTM) EBIT $-310.00m
Free Cash Flow (TTM) Free Cash Flow $-176.00m
Cash position $978.00m
EPS (TTM) EPS $-3.10
P/E forward negative
P/S forward 5.41
EV/Sales forward 0.10
Short interest 12.63%
Show more

Is Arcus Biosciences a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Arcus Biosciences Stock Analysis

Unlock Scores for Free

Analyst Opinions

13 Analysts have issued a Arcus Biosciences forecast:

11x Buy
85%
2x Hold
15%

Analyst Opinions

13 Analysts have issued a Arcus Biosciences forecast:

Buy
85%
Hold
15%

Financial data from Arcus Biosciences

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
258 258
121% 121%
100%
- Direct Costs 10 10
38% 38%
4%
248 248
146% 146%
96%
- Selling and Administrative Expenses 100 100
18% 18%
39%
- Research and Development Expense 448 448
32% 32%
174%
-300 -300
7% 7%
-116%
- Depreciation and Amortization 10 10
38% 38%
4%
EBIT (Operating Income) EBIT -310 -310
9% 9%
-120%
Net Profit -283 -283
8% 8%
-110%

In millions USD.

Don't miss a Thing! We will send you all news about Arcus Biosciences directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Arcus Biosciences Stock News

Positive
Seeking Alpha
about 21 hours ago
Arcus Biosciences presents a high-risk speculation with significant upcoming catalysts, despite recent stock declines and Gilead's exit from the ARC-10 trial. Gilead's continued investment and board presence indicate confidence in Arcus, despite the challenges faced with domvanalimab. Arcus has a diverse pipeline targeting pancreatic and renal cell carcinoma, with promising Phase 3 trials that ...
Neutral
Business Wire
9 days ago
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today announced that the Compensation Committee of the Company's Board of Directors granted twelve new employees options to purchase a total of 42,920 shares of the Company's c...
Neutral
Business Wire
about one month ago
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, announced that its management team will participate in the following upcoming investor conferences in March: Leerink Global Healthcare Conference 2025 Date: Wednesday, March 12th, 20...
More Arcus Biosciences News

Company Profile

Arcus Biosciences, Inc. engages in the development and commercialization of immunotherapies. The firm competes in the segments of the pharmaceutical, biotechnology and other related markets that develop immunotherapies for the treatment of cancer. The company was founded by Terry J. Rosen and Juan Carlos Jaen in 2015 and is headquartered in Hayward, CA.

Head office United States
CEO Terry Rosen
Employees 627
Founded 2015
Website www.arcusbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today